The natural history of glycogen storage disease type Ib in England: A multisite survey

Glycogen storage disease type Ib (GSDIb) is characterized by hepatomegaly and fasting hypoglycaemia as well as neutropaenia and recurrent infections. We conducted a retrospective observational study on a cohort of patients with GSDIb across England. A total of 35 patients, with a median age of 9.1 years (range 1‐39 years), were included in the study. We examined the genotype and phenotype of all patients and reported 14 novel alleles. The phenotype of GSDIb in England involves a short fasting tolerance that extends into adulthood and a high prevalence of gastrointestinal symptoms. Growth is difficult to manage and neutropaenia and recurrent infections persist throughout life. Liver transplantation was performed in nine patients, which normalized fasting tolerance but did not correct neutropaenia. This is the first natural history study on the cohort of GSDIb patients in England.

[1]  M. Veiga-da-Cunha,et al.  Treating neutropenia and neutrophil dysfunction in glycogen storage disease IB with an SGLT2-inhibitor. , 2020, Blood.

[2]  E. Ribeiro,et al.  Glycogen storage diseases: Twenty‐seven new variants in a cohort of 125 patients , 2019, Molecular genetics & genomic medicine.

[3]  G. Bommer,et al.  Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency , 2019, Proceedings of the National Academy of Sciences.

[4]  Alexandros Kouris,et al.  VarSome: the human genomic variant search engine , 2018, bioRxiv.

[5]  J. Calderaro,et al.  Polycystic kidney features of the renal pathology in glycogen storage disease type I: possible evolution to renal neoplasia , 2018, Journal of Inherited Metabolic Disease.

[6]  D. Bartholomew,et al.  Matched unrelated donor transplantation in glycogen storage disease type 1b patient corrects severe neutropenia and recurrent infections , 2018, Bone Marrow Transplantation.

[7]  Dong Hwan Lee,et al.  Novel SLC37A4 Mutations in Korean Patients With Glycogen Storage Disease Ib , 2017, Annals of laboratory medicine.

[8]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[9]  W. Chung,et al.  Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics , 2014, Genetics in Medicine.

[10]  G. Visser,et al.  Liver transplantation in glycogen storage disease type I , 2014, Orphanet Journal of Rare Diseases.

[11]  A. Lapolla,et al.  Quality of life in adult patients with glycogen storage disease type I: results of a multicenter italian study. , 2014, JIMD reports.

[12]  K. Bhattacharya.  Dietary dilemmas in the management of glycogen storage disease type I , 2011, Journal of Inherited Metabolic Disease.

[13]  T. Erbas,et al.  Pituitary hypoplasia and growth hormone deficiency in a woman with glycogen storage disease type Ia: a case report , 2008, Journal of medical case reports.

[14]  C. Hendriksz,et al.  Bone marrow transplantation in glycogen storage disease type 1b. , 2008, The Journal of pediatrics.

[15]  J. Leonard,et al.  Consensus guidelines for management of glycogen storage disease type 1b—European study on glycogen storage disease type 1 , 2007, European Journal of Pediatrics.

[16]  J. Korzenik,et al.  Association of glycogen storage disease 1b and Crohn disease: results of a North American survey , 2007, European Journal of Pediatrics.

[17]  P. Labrune.  Glycogen storage disease type I: indications for liver and/or kidney transplantation , 2007, European Journal of Pediatrics.

[18]  Y. Kohno,et al.  Genetic testing of glycogen storage disease type Ib in Japan: five novel G6PT1 mutations and a rapid detection method for a prevalent mutation W118R. , 2004, Molecular genetics and metabolism.

[19]  L. Faivre,et al.  Long-term outcome of liver transplantation in patients with glycogen storage disease type Ia , 1999, Journal of Inherited Metabolic Disease.

[20]  P. Mullis,et al.  Treatment with low-dose diazoxide in two growth-retarded prepubertal girls with glycogen storage disease type Ia resulted in catch-up growth , 1997, Journal of Inherited Metabolic Disease.

[21]  P. Lee,et al.  Glycogenosis type I and diabetes mellitus: a common mechanism for renal dysfunction? , 2002, Medical hypotheses.

[22]  Yuan-Tsong Chen,et al.  Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. , 2002, Current molecular medicine.

[23]  J. Leonard,et al.  Guidelines for management of glycogen storage disease type I – European Study on Glycogen Storage Disease Type I (ESGSD I) , 2002, European Journal of Pediatrics.

[24]  R. Santer,et al.  Molecular analysis in glycogen storage disease 1 non‐A: DHPLC detection of the highly prevalent exon 8 mutations of the G6PT1 gene in German patients , 2000, Human mutation.

[25]  I. Gérin,et al.  The putative glucose 6-phosphate translocase gene is mutated in essentially all cases of glycogen storage disease type I non-a , 1999, European Journal of Human Genetics.

[26]  I. Gérin,et al.  A gene on chromosome 11q23 coding for a putative glucose- 6-phosphate translocase is mutated in glycogen-storage disease types Ib and Ic. , 1998, American journal of human genetics.